| 12.38 -0.09 (-0.72%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 16.7 | 1-year : | 19.5 |
| Resists | First : | 14.3 | Second : | 16.7 |
| Pivot price | 12.49 |
|||
| Supports | First : | 10.88 | Second : | 8.77 |
| MAs | MA(5) : | 12.61 |
MA(20) : | 12.42  |
| MA(100) : | 9.5 |
MA(250) : | 7.98 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 37.1 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 14.3 | Low : | 4.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MNMD ] has closed above bottom band by 43.6%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.78 - 12.85 | 12.85 - 12.9 |
| Low: | 12.1 - 12.2 | 12.2 - 12.28 |
| Close: | 12.23 - 12.38 | 12.38 - 12.5 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Sat, 18 Oct 2025
A Fresh Look at MindMed (MNMD) Valuation After Breakthrough Phase 2b Results and FDA Recognition - Sahm
Sat, 18 Oct 2025
MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD? - ts2.tech
Tue, 14 Oct 2025
MindMed Announces New Employee Inducement Grant - Business Wire
Tue, 14 Oct 2025
Mind Medicine Nears Pivotal Year: Strong Fundamentals Make It A Buy (NASDAQ:MNMD) - Seeking Alpha
Fri, 10 Oct 2025
Mind Medicine (MindMed) Inc. (MNMD): Analyst Ratings Signal a Potential 90% Upside for Biotech Investors - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 55.7 (%) |
| Shares Short | 9,860 (K) |
| Shares Short P.Month | 10,190 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.6 % |
| Return on Equity (ttm) | -59.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -102 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -9.24 |
| PEG Ratio | 0 |
| Price to Book value | 5.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|